ertumaxomab
risankizumab
lucatumumab
milatuzumab
apolizumab
spesolimab
labetuzumab
cergutuzumab
cancroid
nimotuzumab
squamous cell carcinoma
sipuleucel
oportuzumab monatox
periphilin
alacizumab
dermatoma
tremelimumab
tisotumab
samalizumab
-les-
resiquimod
pritumumab
brentuximab
immunocytokine
deruxtecan
myxomatosis
intrabody
taplitumomab
dermatolymphangioadenitis
olendalizumab
minretumomab
skin cancer
amatuximab
amivantamab
durvalumab
vaccinide
corneocyte
monoantibody
-mab
dermatofibrosarcoma
nacolomab tafenatox
ozoralizumab
tabalumab
pemtumomab
detumomab
vaccination
antipolyvalent
acasunlimab
-tum-
dermadrome